Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octanorm (cutaquig) in Primary Immunodeficiency Diseases
NCT03988426Phase 3Completed
- Sponsor
- Octapharma
- Start
- Mar 2017
- Primary completion
- Jan 2018
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of polyvalent human immunoglobulin in primary immunodeficiency disease (PID), sponsored by Octapharma. Primary endpoint: Serious Bacterial Infections at 24 weeks. Started Mar 2017; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT03988426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03988426.